Peptide Directory

Peptides, and what the record actually shows

A seller with a GLP-1 on the shelf usually has a peptide next to it. The grouping below runs on the weight of published evidence rather than on the body part being marketed, since the seller page rarely puts those two things side by side. Each guide cites primary research, and a thin record is stated on the card before you click.

Most of the peptides listed here hold no FDA approval and reach patients through compounding pharmacies. Read this as background rather than medical advice, and take any decision to a licensed clinician.

Related: what GLP-1s are prescribed for, by condition and the seller reviews.

A low grade is a finding

A weak grade does not mean the compound does nothing. It means nobody has run the study that would settle it, and that absence is itself the result. Sellers price the promising ones the same as the proven ones.

Compounded is not approved

An FDA approval attaches to a named product from a named manufacturer. A compounded peptide is prepared by a pharmacy against a prescription and carries no such approval. That is how the supply chain works, not an accusation about any one seller.

The headline is rarely the rate

Peptide pricing behaves like GLP-1 pricing. The advertised figure is often a first month, a membership fee, or a multi-month prepay divided out. The seller review is where the standing rate is written down.

Grade A — approved, or strong randomized evidence

An FDA-approved product for this use, or randomized trials large enough to rely on.

Grade B — real trials, real limits

Human trials exist and point one way, but they are small, short, or run in a narrower population than the people being sold it.

Grade C — mechanism and anecdote, not outcomes

A plausible mechanism, animal work, or small uncontrolled series. Nothing here establishes that it does what the seller says in humans.

Grade D — sold well ahead of its evidence

Marketed widely with little or no human outcome data behind the claim.